retatrutide clinical trial south africa VisualAbstract: reduces body weight by 17.5% in patients with obesity RETATRUTIDE HAS NOT BEEN APPROVED

Blood pressure, heart rate, cholesterol, blood sugar, waist circumference, sleep quality, inflammation, and fitness level all matter

All statistical analyses were performed using Prism 5 (GraphPad Software, CA)

Losing weight is a challenge for several reasons, and with obesity rates being at an all-time highnearly 1 in every 3 adults (30.7%) are overweightmillions of them are searching for an effective solution

On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002

Our goal is to make the process simple so you can focus on your health goals with support every step of the way

A 2022 study published in Nutrients reported that certain polyphenol-rich plant extracts directly up-regulated GLP-1 in vitro and in vivo